MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi July 18, 2019 - NASDAQ Companies 0 » View More News for July 18, 2019
